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ABSTRACT
The cancer chemotherapeutic agent doxorubicin (DOX), Adriamycin, is part of the treatment
regimen for breast, ovarian, small cell lung cancer and acute/chronic lymphoid leukemia.
Adverse effects associated with DOX are cardiotoxicity and nephrotoxicity. Interventions are
needed to reduce DOX nephrotoxicity. Resveratrol (RES) is a phytochemical contained in
grapes, berries and nuts, which possesses antioxidant and anticancer properties. This study tested
the hypothesis that RES will attenuate DOX renal cytotoxicity in human noncancerous renal
proximal tubular epithelial (HK-2) cells and that RES will reduce DOX mediated changes in
mitochondrial function. HK-2 cells were plated and grown for 48 hours (h). Cells were next preincubated for 1h with 0 (DMSO), 5 or 7.5 µM RES followed by a 24 h co-incubation with 0-5
µM DOX. RES did not alter cell growth or viability at the concentrations tested as indicated by
comparable MTT values between DMSO and RES groups (p>0.05). Cell viability was further
assessed by cell count using Trypan blue exclusion. DOX produced a concentration dependent
decline in viability within a 24 h exposure. Pretreatment for 1 h with RES was sufficient to
reduce DOX loss of cell viability. Studies were initiated to investigate the cellular mechanism of
RES attenuation of DOX cytotoxicity. Western blot of cells following 24 h exposure examined
increased protein carbonylation as an indicator of oxidative stress. Initial studies were begun to
examine the DOX effects on mitochondrial oxygen consumption using a Seahorse platform. In
summary, RES did not diminish cell viability at the concentrations tested in our HK-2 cells.
DOX diminished cell viability within 24 h relative to vehicle control. A 1 h pretreatment with
RES reduced DOX cytotoxicity in HK-2 cells. Prevention of mitochondrial impairment and
oxidative stress by DOX are potential mechanisms for RES protection in HK-2 cells.
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CHAPTER 1
INTRODUCTION: DOXORUBICIN
Doxorubicin: Cancer Chemotherapeutic Agent
Doxorubicin (DOX), trade name Adriamycin, is an anthracycline cancer
chemotherapeutic that has been used in the treatment of a variety of cancers including: breast,
ovarian and small cell lung cancers and both acute and chronic lymphoid leukemias (Figure 1).
The first anthracycline, daunorubicin, was isolated in 1951 and its analogue, DOX, was
developed in 1969 (Arcamone, 1967). DOX is an antitumor antibiotic that was originally isolated
from the Streptomyces peucetius bacteria. The longevity and continued use of the drug, it was
first approved for use in the United States in 1974, are a testament to the drug's efficacy.
Typically DOX is administered in intravenous doses of 60 to 75 mg/m2 every 21 to 28 days
(National Library of Medicine, 2017). The dosage varies based upon: indication, body surface
area and hepatic function (National Library of Medicine, 2017). The mechanism of action for
DOX involves intercalating between base pairs of deoxyribonucleic acid (DNA) and inhibiting
macromolecule biosynthesis (Gu et al., 2016). The effectiveness of DOX is related to its ability
to inhibit DNA replication through the inhibition of topoisomerase II (Top2) by preventing the
ligation of nucleotide strands after double strand breakage (Eissa, El-Naggar, El-Sattar, &
Youssef, 2017). The DNA strand requires unwinding for both transcription and replication.
However, the unwinding has to be compensated by overwinding elsewhere in the DNA molecule
(Nitiss, 2009) This problem of supercoiling is addressed through topoisomerases that introduce
DNA double strand breaks that eliminate the overwinding of the DNA molecule. Top2
introduces double strand breaks altering DNA structure, replication, transcription and
chromosome segregation that are essential processes in preventing tumor growth (Nitiss, 2009).
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The inhibition of Top2 triggered by DOX administration is directly correlated with the drug’s
effectiveness as a cancer chemotherapeutic agent.

Figure 1: Chemical Structure of Doxorubicin
The same mechanisms that make DOX an effective antineoplastic agent are also in part
responsible for the drug’s adverse effects. Administration of DOX has been limited by dosedependent, irreversible and progressive toxicity (Buzdar et al., 1992). DOX direct cytotoxic
action on membranes leads to redox cycling, generation of reactive oxygen species (ROS)
(Cappetta et al., 2017) and subsequent lipid peroxidation and DNA damage (Gewirtz, 1999). The
metabolism of DOX (Figure 2) through reductive pathways leads to the generation of a
semiquinone free radical, doxorubicinol (DOX-OL) and ROS (Riddick et al., 2005). Studies have
shown that an intravenous bolus of DOX produces high plasma concentrations that quickly fall
due to rapid and extensive distribution into tissues (Speth, Linssen, Holdrinet, & Haanen, 1987).
Independent of the absolute drug concentration in plasma, 50 to 85% of plasma DOX is bound to
protein, leaving 50% of DOX and its metabolite DOX-OL as free drug (Celio, Digregorio, Ruch,
Pace, & Piraino, 1982). After 50% of DOX is removed from the body unchanged the remaining
50% is metabolized to DOX-OL via a two-electron reduction (Joerger, Huitema, Meenhorst,
Schellens, & Beijnen, 2005). Other metabolites are formed but are detected at much lower
concentrations (Joerger et al., 2005). Elimination primarily occurs in the bile (Takanashi &
2

Bachur, 1976) and over 50% is eliminated as part of the “first pass effect” through the liver
(Harris & Gross, 1975). There has been no evidence to indicate that enterohepatic recirculation
occurs with DOX administration (Takanashi & Bachur, 1976). Patients have described a reddish
discoloration of urine and further examination indicated only about 5% of a dose was discovered
in urine (Di Fronzo, Lenaz, & Bonadonna, 1973). The mean half-life of DOX has been estimated
to be between 1-3 hours. It should also be noted that DOX concentrations measured in healthy
tissues such as liver, spleen, lymph nodes, muscle, hematopoetic cells, kidney and lung always
exceed plasma concentrations (Chan et al., 1978; J. Cummings & McArdle, 1986; Y. T. Lee,
Chan, Harris, & Cohen, 1980; Speth, van Hoesel, & Haanen, 1988). The unique features of drug
accumulation and distribution associated with DOX are part of the reason it is an effective
antineoplastic agent in the treatment of a variety of cancers. DOX has a propensity to accumulate
in tissues over time and it is this accumulation that may predispose tissues to cytotoxicity.
Toxicities associated with DOX have limited its clinical usage. Common side effects
include bone marrow suppression, nausea, vomiting, diarrhea, headache, skin rash, dizziness,
confusion, neuropathy, alopecia and fever (National Library of Medicine, 2017). The more
severe adverse reactions that are associated with high doses or prolonged therapy are
cardiotoxicity, hepatotoxicity and nephrotoxicity and are major dose limiting effects. The
mechanisms associated with various toxicities have not been fully elucidated but a disturbance in
the antioxidant-oxidant system leading to free radical generation and iron-dependent oxidative
damage has been implicated in previous studies (Liu, Li, Xia, Li, & Shao, 2007). Additionally,
DOX has been shown to induce inflammatory changes in heart, liver and kidney tissue (Deepa &
Varalakshmi, 2005). The tissue damage caused by DOX produces an imbalance between free
radicals and antioxidants that is demonstrated by lipid peroxidation and protein modifications
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leading to tissue damage (Ayla et al., 2011). The free radicals formed as a result of the
conversion of DOX to DOX-OL cause damage by inducing oxidative stress and subsequent
tissue damage. Increased levels of DOX-OL in human myocardium have been shown to cause
impairment of hydrolase and/or reductase deglycosylation and to uncouple hydrolysis from the
carbonyl reduction causing increased levels of the redox-cycling metabolite (Licata, Saponiero,
Mordente, & Minotti, 2000). DOX cardiotoxicity has been linked to the DOX-OL metabolite
which compromises both systolic and diastolic cardiac function more than the parent compound
DOX (Olson et al., 1988). The NADPH: Cytochrome P450 reductase (P450R) enzyme catalyzes
the one electron reduction of DOX to the semiquinone free radical, which can be directly
cytotoxic leading to covalent modification of macromolecules (Riddick et al., 2005). This
quinone-structured agent can be enzymatically reduced and may subsequently autoxidize,
generating free radicals (Goodman & Hochstein, 1977). The free radicals produced are the
superoxide anion, hydrogen peroxide and the hydroxyl radical (Goodman & Hochstein, 1977).
However, it should also be mentioned that the P450R enzyme also plays a role in the DOX
detoxification pathway involving reductive deglycosylation to the metabolite, 7-deoxyglycone
(Niitsu, Kato, Shikoshi, & Umeda, 1997). The effectiveness of DOX as an antineoplastic agent is
well documented but there is a need to find better methods to combat the drug’s multiple
toxicities.
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Figure 2: Major pathway of doxorubicin metabolism in humans
Doxorubicin Toxicity: Heart
The effects of DOX on the heart are both acute and chronic, meaning that even after the
therapy is discontinued the accumulated drug can lead to left ventricular dysfunction, dilated
cardiomyopathy and heart failure (Lipshultz et al., 2010). The effects on the heart are more
pronounced in part due to its lower levels of protective antioxidant enzymes such as superoxide
dismutase, which results in cardiomyocytes having a greater susceptibility to injury over other
tissues (Barry, Alvarez, Scully, Miller, & Lipshultz, 2007). The severity of heart disease is linked
directly to accumulated DOX dosage during the course of therapy ranging from 3-5% in patients
who received a cumulative dose of 400mg/m2 to 18-48% in patients receiving 700mg/m2
(Lipshultz et al., 2010). DOX induced cardiotoxicities are clearly a dose-dependent response.
Studies have shown that the various DOX manifested cardiotoxicities can be attributed to the
excessive production of ROS causing damage to cardiomyocytes. Cardiomyocytes require
mitochondria for extensive ATP production that ensures contractile function of the heart (Koleini
& Kardami, 2017). Oxidative stress activates molecular pathways causing the loss of
cardiomyocytes through necrosis and apoptosis (Licata et al., 2000). The oxidative stress
5

mechanism of DOX has also been shown to mediate mitochondrial toxicity, a key player in acute
and long-term cardiac dysfunction (Zhang, Shi, Li, & Wei, 2009). Ichikawa and colleagues have
shown there is also a preferential accumulation of Iron (Fe2+) in the mitochondria following
treatments and isolated cardiomyocytes showed an increase in Fe concentrations for both
mitochondrial Fe2+ and cellular ROS levels (Ichikawa et al., 2014). The excessive amount of
ROS and substantial increases in Fe2+ are two ways that DOX has been shown to cause acute and
chronic cardiac toxicities.
Doxorubicin Toxicity: Liver
The liver achieves the highest concentration of DOX compared to all other organs studied
(Y. T. Lee et al., 1980). This distribution of DOX was observed in patients about 1-1.5 hours
after an intravenous bolus dose with the highest levels of uptake, 2.3-19.8µg/g, occurring in the
liver compared to plasma levels of 0.2-0.53 µg/g (Y. T. Lee et al., 1980). The aforementioned
distribution would indicate that the liver plays a central role in DOX metabolism and
distribution. In the past, hepatic impairment has led to a dose reduction or removal of the
medication entirely from a chemotherapeutic regimen. Hepatic dysfunction is also mediated
through the generation of free radicals causing oxidative damage to tissue. The high levels of
P450 enzymes in the liver make it a direct target for drug accumulation and potential damage.
The P450R facilitated conversion of DOX to its toxic metabolite DOX-OL occurs in the liver.
The toxic effects are seen with increases in aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) in stressed erythrocytes (Hamlaoui et al., 2012). High malondialdehyde
(MDA) has also been used as a diagnostic marker of hepatic impairment. The increased levels of
MDA, AST and ALT within erythrocytes have been accompanied by a concomitant decrease of
antioxidant enzymes in both regions of the liver (Hamlaoui et al., 2012). The increase in free iron
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(Fe2+), hydrogen peroxide (H2O2), coupled with depressed Ca2+ levels, and followed by the
induction of the hydroxyl radical (•OH) that can in turn affect Ca2+ homeostasis in both
erythrocytes and plasma (Bengaied, Ribiero, Amri, Scherman, & Arnaud, 2017). Kassner and
colleagues reported that the extrinsic and intrinsic apoptotic responses mediated by Fas and Bax
were both associated with DOX-induced acute hepatic damage (Kassner et al., 2008). The
reduction of DOX to DOX-OL detected in the cytosol of the liver has the highest Vmax and
clearance values making it a primary target for the drug’s metabolism as well as the adverse
effects associated with DOX (Kassner et al., 2008).
Doxorubicin Toxicity: Kidney
The effects of DOX associated toxicities have been studied much less extensively in the
kidney as compared to other organs. However, DOX-induced mechanisms of nephrotoxicity are
postulated to be as a result of free radical generation similar to what has been reported to
contribute to hepatotoxicity and cardiotoxicity, along with preferential accumulation of DOX in
the kidney leading to direct renal damage (Refaie, Amin, El-Tahawy, & Abdelrahman, 2016).
The preferential accumulation of DOX in the kidney leads to increased capillary permeability
and glomerular atrophy (Injac et al., 2008). Although the exact mechanism is unknown, there is
ample data to suggest that free radical formation, iron-dependent oxidative damage of biological
macromolecules and membrane lipid peroxidation are again the key players in DOX-induced
toxicity (Liu et al., 2007). The possible role of DOX in nitric oxide synthase (NOS) metabolism
is through direct or indirect stimulation of nitric oxide (NO) production and could be attributed
to the increase in free radical generation mediated by the drug (Ayla et al., 2011). Nitric oxide
(NO) can act as a cytoprotective or cytotoxic agent and is generated by endothelial nitric oxide
synthase (eNOS) or inducible nitric oxide synthase (iNOS) (Nathan & Xie, 1994). Free radical
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production and/or NO release induced by DOX may lead to toxicity in the kidney. The
significant change in kidney tissue triggered by DOX administration is exemplified by the
cytotoxic effects on human noncancerous renal proximal tubular epithelial cells (HK-2) causing
alterations in caspase pathways (Y. Wu et al., 2009). Alterations in caspase pathways alter
apoptosis.
Damage to the liver as well as the heart may also indirectly effect DOX induced
nephropathy and nephrotoxicity. The kidneys receive nearly 25% of cardiac output and as one of
the major organs of excretion, are exposed to a greater proportion of circulating drugs (Y. Wu et
al., 2009). The known cardiac toxicities associated with the drug may more directly affect the
kidney than previously believed and should be examined more thoroughly. DOX has also been
shown to accumulate at high levels in the mitochondria increasing Fe2+ levels within the
mitochondria as well as increasing cellular reactive oxygen species (Ichikawa et al., 2014). DOX
has the ability to interact with Fe directly and forms a DOX-Fe2+ complex, resulting in Fe2+
cycling between Fe(II) (Niitsu et al., 1997) and Fe(III) forms producing a substantial amount of
ROS (Ichikawa et al., 2014). The same study showed that DOX mitochondrial content was
significantly greater than DOX content in the cytosol, 0.8µM and 0.01 respectively upon
administration of 20 µM/mg dose. Additionally, DOX-Fe2+, measured as Mito 55Fe content, in
the mitochondria was almost twice that of the control. DOX toxicity to the mitochondria in the
heart, as well as the kidney, shows that mitochondrial damage plays a central role in DOXinduced complications. Attenuating DOX mitochondrial toxicity may play a central role in
mitigating nephrotoxicity and will be examined in this study.
INTRODUCTION: RESVERATROL
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Resveratrol (3,4’,5-trihydroxystilbene) (RES) is a naturally occurring polyphenolic
compound found in various nuts, berries and grapes and exhibits antioxidant properties and antiinflammatory activity (Valentovic et al., 2014) (Figure 3). RES is a phytoalexin that is produced
by plants as a defense mechanism triggered by conditions of fungal growth, specifically powdery
mildew. The main enzyme responsible for RES biosynthesis is stilbene synthase that condenses
one p-coumaroyl-CoA and three molecules of malonyl-CoA (Park & Pezzuto, 2015). Despite its
early isolation in 1939, RES has only gained attention relatively recently for its numerous
antioxidant and anti-inflammatory benefits. In 1997, Jang and colleagues discovered the
chemopreventive effects of RES and its ability to inhibit events associated with tumor initiation
e.g. free radical formation (Jang et al., 1997). Further studies have concluded that RES has both
anti-angiogenic and anti-tumor effects in skin, breast, colorectal, prostate and lung cancers (Park
& Pezzuto, 2015). RES’s anti-oxidant and anti-inflammatory properties have been shown to
exert positive effects on the heart, liver and kidney in addition to its known chemopreventive
effects.
The pharmacological properties of RES can make research somewhat limiting. RES is
known to have high absorption but extremely poor bioavailability (<1%) when administered
orally. RES undergoes rapid metabolism and excretion and most of the oral dose is recovered in
urine unchanged. However, oral intake remains the major route administration and has been

Figure 3: Chemical structure of Resveratrol
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studied extensively. RES exists as both cis and trans isomers; however, most studies use the
trans isomer due to greater stability. Improvements have been made in identifying RES and its
metabolites using high performance liquid chromatography (HPLC) analytical methods. HPLC
has enabled direct identification of metabolites and the position of the hydroxyl substitution. This
new method led to the development of a metabolite standard and has enabled the measurement of
RES derivatives (Cottart, Nivet-Antoine, Laguillier-Morizot, & Beaudeux, 2010). The
advancement of analytical methods has also contributed to identifying free and bound forms of
RES in plasma. RES is lipophilic, and therefore, it is necessary to take into account LDL-and
protein bound fractions (Cottart et al., 2010). In 2008 it was described in vitro, that more than
90% of free trans RES is bound to human plasma lipoproteins in a non-covalent manner in
healthy human subjects (Burkon & Somoza, 2008). A full understanding of the pharmacokinetics
and bioavailability is essential in determining proper dose and response of RES, and only then
can it be utilized to its full potential in the treatment of disease. RES’s ability in slowing or
halting disease progress has been widely studied in the past few years and will be discussed in
the following subsections. There is little doubt that the potential clinical usage of antioxidant
RES could have far reaching applications in the mitigation of a number of disease pathologies.
Resveratrol and Cancer
Jang and colleagues discovered the chemopreventive properties of RES by demonstrating
the anti-initiation, anti-promotion and anti-tumor progression actions of RES in different models
(Jang et al., 1997). Potential mechanisms proposed for RES anticancer activity include action as
an antioxidant and/or anti-inflammatory agent, interference with signal transduction pathways,
modulation of cell cycle regulating proteins and selective induction of apoptosis, which has been
characterized in various cell lines (Ulrich, Wolter, & Stein, 2005). RES anti-tumor effects and
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pathways have been studied broadly in vitro on various cell lines but there are still very limited
clinical applications available. The need for further studies on human cell lines is imperative in
determining the possible uses of RES as a chemotherapeutic agent.
Resveratrol and the Heart
Resveratrol has long been part of the “French paradox” and in 1992, Renaud and
colleagues showed that the French population had a lower risk of cardiovascular disease (CVD)
even though their diet was high in saturated fats. The intake of a moderate amount of RES
containing red wine was thought to play a potential protective role against CVDs. Further studies
showed RES as being a good candidate for prevention of CVD due to its apparent protection of
vascular walls on oxidation, inflammation, platelet oxidation and thrombus formation (Delmas,
Jannin, & Latruffe, 2005). Cardioprotective mechanisms of RES are in part due to its ability to
upregulate eNOS which in turn favors NO mediated vasodilation (Leikert et al., 2002; Wallerath
et al., 2002). The known physiological roles of NO show that it improves vasodilation and
decreases platelet aggregation as well as stimulating leukocyte recruitment and proliferation of
smooth muscle cells (H. Li & Forstermann, 2000). Previous studies have also shown that RES
can protect against oxidative stress by scavenging the hydroxyl and superoxide radical
(Bonnefont-Rousselot, 2016). These same RES scavenging properties that prevent against
oxidative stress are also involved in the prevention of lipid peroxidation. The identification of
multiple targets, as well as the known protective benefits against CVDs, make naturally
occurring RES a noteworthy compound for future study in disease prevention.
Resveratrol and the Liver
Hepatotoxicity is not only a major problem in the development of drugs, but is also one
of the major reasons certain drugs are withdrawn from the market. Clinically, drug-induced liver
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injury is the most frequent cause of acute liver failure (Pagliarini et al., 2008) in the west (E. S.
Lee, Shin, Yoon, & Moon, 2010). RES has been shown to protect against numerous in vitro and
in vivo rodent models of liver injury, including hepatotoxicity caused by drugs and other
xenobiotics (Bishayee, Darvesh, Politis, & McGory, 2010). The proposed mechanism of RESmediated protection against liver injury is that it acts as an antioxidant and decreases oxidative
stress by directly scavenging free radicals or by upregulating cellular antioxidant enzymes such
as superoxide dismutase (SOD), catalase and glutathione peroxidases (McGill, Du, Weemhoff, &
Jaeschke, 2015). Inflammation often accompanies liver disease and the anti-inflammatory
properties of RES have been demonstrated by the downregulation of inflammation-inducing
biomarkers including proinflammatory mediators, oxidative stress markers and endogenous
vasoconstrictors, while accompanied by the upregulation of inflammation-reducing biomarkers
and anti-inflammatory proteins (Park & Pezzuto, 2015). The poor bioavailability of RES and its
rapid and extensive metabolism in the liver continues to be an obstacle in clinical application and
further metabolic studies are needed to validate its potential as a prospective therapeutic option.
Resveratrol and the Kidney
The positive effects that RES could potentially exert on the kidney have not been
examined as closely as with other organs. Pharmacokinetic studies indicated that RES levels are
higher in the kidney and liver compared to other organs suggesting that RES has a greater
potential to induce its effects on these organs respectively (Aggarwal et al., 2004). RES has been
shown to alleviate oxidative stress in a diabetic kidney and attenuate increases in
proinflammatory mediators (Palsamy & Subramanian, 2011), but little is known about its
potential to reduce or protect against xenobiotic-induced nephrotoxicity. Previous studies
completed in our lab have shown that pretreatment with RES, when co-administered with
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cisplatin (a well-known cancer chemotherapeutic agent) demonstrated positive effects in the
mitigation of nephrotoxicity. The results have shown that pretreatment with RES was protective
for cisplatin renal cytotoxicity in an in vitro mouse model. Additionally, RES protection was
associated with prevention of lipid peroxidation and oxidative stress that is normally associated
with cisplatin administration (Valentovic et al., 2014).
Resveratrol and the Mitochondria
Mitochondria are cytoplasmic double-membraned organelles that play a crucial role in
cell physiological processes, e.g. energy generation via formation of adenosine triphosphate
(ATP) through oxidative phosphorylation (Trumbeckaite et al., 2006). Oxidative phosphorylation
leads to two electron transfer through the electron transport chain that is organized into five
different trans-membrane protein complexes I-V (Dias & Bailly, 2005). Mitochondria are a
common target of toxicity for drugs and other chemicals, and damage results in decreased
aerobic metabolism and cell death (Beeson, Beeson, & Schnellmann, 2010). Mitochondrial
dysfunction plays a role in the pathophysiology of many human diseases, as well as in the
initiation and progression of apoptosis and the production of ROS in cellular systems. The roles
of these tiny powerhouses range from apoptosis to energy homeostasis and cell signaling to lipid
metabolism, making it evident that proper mitochondrial function is imperative to a variety of
biological processes. RES may modulate mitochondrial function by regulating transcription
factors that activate or repress mitochondria-related genes, causing alterations in mitochondrial
physiology (de Oliveira et al., 2016). Proper mitochondrial function is essential but
mitochondrial biogenesis, which restores cell vitality, is imperative. It has been proposed that
recovery of organ and cellular injury following insult, may be limited by the remaining
mitochondrial function and ATP levels, and that stimulation of mitochondrial biogenesis may
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promote organ recovery and restore cellular function in the short and long term (Beeson et al.,
2010). RES has previously been shown to induce mitochondrial biogenesis as assessed through
respirometric measurement when compared to untreated control cells (Beeson et al., 2010). The
mechanism by which RES can induce mitochondrial biogenesis is not known but it is possible
that it may work through inducing peroxisome proliferator-activated receptor gamma coactivator
1-alpha (PGC1α), the “master regulator” of mitochondrial biogenesis (Beeson et al., 2010). The
anti-inflammatory and antioxidant properties of RES may serve to protect mitochondria against
dysfunction induced by xenobiotics as well as to promote mitochondrial biogenesis. This twofold protective response could potentially mitigate mitochondrial toxicity seen with not only
DOX administration but also a variety of other drugs. Although RES has been shown to have
effects on mitochondrial function, the exact mechanism and dynamics by which RES modulates
function are not fully understood (de Oliveira et al., 2016). As such, there is a need for further
study to examine the effects of RES on modulating and possibly protecting mitochondrial
function in the presence of oxidative stress induced by anthracyclines, e.g. DOX.
Statement of Hypothesis
The effectiveness of DOX as a cancer chemotherapeutic agent is well documented in a
variety of different types of cancers. However, it is clear that the various toxicities associated
with the drug limit its clinical use; thus, new methods designed to reduce toxicity are vital to its
continued clinical usage. The previous discovery by our lab, showing that RES decreased the
extent of oxidative stress and associated modification of proteins, has led us to consider the
possible effects of using RES to mitigate DOX induced nephrotoxicity. Additionally, we wanted
to determine if RES’ antioxidant and anti-inflammatory properties would also protect against
mitochondrial dysfunction. Previous studies have shown that DOX accumulates at high levels in
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the mitochondria; therefore, we hypothesized that RES would reduce DOX renal cytotoxicity in
HK-2 cells and that RES would attenuate DOX-mediated changes in oxidative stress and
mitochondrial function.
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Chapter 2
Materials and Methods
Chemicals and Reagents
DOX and RES were purchased from Sigma Aldrich (Item No. D1515 and Item No.
R5010) and were used throughout the experiment. All other chemicals were purchased from
Fisher Scientific or Sigma Aldrich Company and were of the highest analytical quality. Antibody
sources and dilutions are described below in the appropriate subsection(s).
Cell Line and Treatment
Human immortalized epithelial (HK-2) cells were purchased from the American Type
Culture Collection (ATCC) and cultured according to the manufacturer’s guidelines. Cells were
grown in keratinocyte-free media with 50µg/mL bovine pituitary extract and 5 ng/mL
recombinant epithelial growth factor from Invitrogen (Carlsbad, CA, USA, Item No. 17005-042).
Cells were grown in a humidified incubator under constant conditions of 37° and 5% CO2. HK-2
cells were plated into six-well tissue culture plates (1.5x106 cells/well) (Corning, Sigma Aldrich
Item No. CLS3516) and allowed to grow for 48 h. Media was replaced and cells were treated
with 0.5 or 7.5 µM of RES or 0, 1 or 2 µM of DOX for 24 h. Vehicle controls were equal
amounts of Dimethyl sulfoxide (DMSO) (Item No. TS-20688) for RES or purified water for
DOX, respectively. Following the 24 h treatment period, cells were collected with TrypsinEDTA (0.25%) (Invitrogen, Item No. 25200072) for sample analysis.
Cell Viability
Cells were plated in 48-well tissue culture plates (39,000 cells/mL) (Cyto One, USA
Scientific, Ocala, FL, USA, Item No. CC7682-7548) and allowed to grow for 48 h in the manner
listed in the above sub-section. In later experiments, cells were plated in 96-well tissue culture
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plates (3700 cells/mL) (Thermo Fisher Scientific, Item No.12565501) and allowed to grow for
48 h in the same manner. Following the treatment period, cell viability was assessed using the
MTT assay (van Meerloo, Kaspers, & Cloos, 2011). The MTT assay relies on the conversion of
tetrazolium dye 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma
Aldrich, Item No. M5655-5X1G) to formazan by NAD(P)H-dependent oxidoreductases. The
cells were incubated at room temperature for 4 h with MTT, and quantity was specified in 25mL
of HBSS (Hank’s buffered salt solution) (Gibco, Thermofisher Scientific, Pittsburgh, PA, USA,
Item No. 14025076). Following the 4 h incubation with MTT, cell viability was assessed using a
plate reader (Synergy 2, Biotek Instruments, Winooski, Ca, USA) at 540 nm by measuring
formazan concentration as reflected in optical density (OD). Cells not exposed to DOX or RES
were compared to values of the wells that were exposed to the drugs.
Western Blot
Western blot analysis was conducted to assess the expression of cytochrome-C
oxidoreductase IV. Protein concentration in each sample was determined using the Bradford
protein assay (Bradford, 1976). A 40 µg aliquot of each sample was denatured by boiling for 5
min. Proteins were then separated on a 12.5% polyacrylamide gel and transferred to a
nitrocellulose membrane (Bio-Rad, Hercules, CA, USA, Item No. 162011). Successful transfer
and unified protein loading were verified using MemCode Reversible Protein Stain Kit (Pierce
Biotechnology, Rockford, Il, USA, Fisher Scientific, Item No. PI-24580). Membranes were
blocked in 5% milk/TBST solution (10mM Tris-HCl, 150mM NaCl, 0.1% Tween-20; pH 8.0)
for 1 h. Membranes were then incubated with continuous shaking overnight at 4°C with
cytochrome C (Cell Signaling, Item No.4272, 1:1000 dilution). The membranes were washed
four times with TBST, and goat anti-rabbit HRP-linked secondary antibody (Santa Cruz, Item
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No. sc-2004) was diluted 1:5000 in 5% milk/TBST and added for 1 h with continual shaking.
The membranes were washed again with TBST in the same manner listed above. Membranes
were developed using Amersham ECL Western Blotting Detection Agent (GE Healthcare Life
Sciences, Malborough, MA, USA, Item No. RPN2232). A Bio-Rad Chemidoc system was to
capture the gel image for densitometry analysis. All western analyses were conducted as three
independent experiments. Western blot was also conducted as described above using rabbit
polyclonal antibody to peroxisome proliferator-activated receptor gamma coactivator 1-alpha
(anti-PGC-1α) (Abcam, Item No. ab191838) and sirtuin 1 (anti-SIRT1) (Abcam, Item No.
ab7343) both diluted 1:1000 in 5% w/v milk/TBST. Human heart tissue whole cell lysate,
(Abcam, Item No.7919 dilution 1:1000) a positive control known to express PGC-1α, and SIRT1
was used in both PGC-1α and SIRT1 analyses at a dilution of 1:1000 and boiled for five minutes
prior to loading. Following washing with TBST, membranes were treated with goat anti-rabbit
HRP-linked secondary antibody for 1 h (Santa Cruz, Item No. sc-2004) and secondary was
diluted 1:3000 in 5% w/v milk/TBST. Membranes were washed and developed as previously
described. PGC-1α positive control was replaced with mouse heart total protein lysate (Abcam,
Item No. Ab30291). SIRT1 positive control was replaced by human embryonic kidney whole
cell lysate (HEK293). Dilutions for both positive controls were 1:1000 and were boiled for 5
minutes prior to loading. Secondary antibodies and dilutions remained unchanged.
Oxidative Stress
Protein carbonylation is an indicator of oxidative stress that produces an aldehyde or
ketone side chain on amino acids. Protein carbonylation was assessed using the Oxyblot Protein
Oxidation Detection Kit (EMD Millipore, Billerica MA, USA, Item No. S7150). Following a 24
h treatment with vehicle(s), DOX, RES or DOX and RES, cells were trypsinized, pelleted and
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stored in lysis buffer at -80°C until the blot was performed. The Bradford assay measured protein
content and a 25 µg aliquot was derivitized as described in the previous sub-section. Proteins
were separated on a 12.5% polyacrylamide gel, transferred to a nitrocellulose membrane and
uniform protein loading was verified using MemCode Reversible staining as described in the
previous sub-section. Protein carbonyl moieties on amino acids generated by oxidative stress
were derivitized in the presence of 2,4-dinitrophenylhydrazine to stable 2,4dinitrophenylhydrazone groups. The membrane was blocked for 1 h in 1% BSA in PBST
(Phosphate buffered saline, 0.05% Tween-20 pH 7.2-7.5). The primary antibody used recognizes
2,4-dinitrophenylhydrazine groups on proteins and was used at a dilution of 1:150 and incubated
with constant shaking overnight at 4°C. The membrane was washed in PBST four times for 10
minutes and incubated with secondary antibody at a dilution of 1:300 in 1%BSA/PBST for 1 h at
room temperature. The membrane was washed again in the same manner listed above. Results
were analyzed with BioRad Chemidoc densitometry software (version 4.0.1, Catalog No. 1709690, BioRad, Hercules, CA, USA).
Seahorse XFp Assays
Seahorse XFp assays allow measurement of basal Oxygen Consumption Rate (OCR) and
Extracellular Acidification Rate (ECAR) following injection of compounds to identify sources of
mitochondrial impairment. Mitochondrial function was measured using Agilent mitochondrial
stress and glycolytic stress assays. Cells were cultured in XFp miniplates (75,000 cells/mL)
(Agilent Technologies, Item No. 103025-100). Prior to the assay, cells were washed with assay
media (Agilent Technologies, Item No. 103334-100) supplemented with 1mM pyruvate, 2 mM
glutamine and 0 mM glucose and equilibrated in 180 µL pre-warmed assay media at 37°C with
no CO2 for 1 h. Cells were treated and incubated for 24 h with the varying drug concentrations or

19

vehicle controls. In each assay, three basal OCR/ECAR measurements were taken at 7-minute
intervals using the Seahorse XFp instrument system. Following basal measurements, various
probes were injected and additional OCR and ECAR measurements were taken. Maximal
respiration was stimulated by the addition of carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP), a mitochondrial uncoupler. The mitochondrial stress test assay
(Agilent Technologies, Item No. 103015-100), injections of oligomycin (0.05µM), and a mixture
of rotenone/antimycin A (0.05µM) were added and OCR and ECAR were measured. In the
Glycolysis Stress Test (Agilent Technologies, Item No. 103020-100), glucose (10mM),
oligomycin (1µM), and 2-DG were injected, and OCR and ECAR were measured. Upon
completion of each assay, cells were washed with 200µL PBS and lysed. Protein concentration
was determined using the Bradford assay as previously described. Results were normalized to
total protein concentration and analyzed using Wave Software (Agilent Technologies, Wave for
Desktop, Version 2.3.0.19).
Statistical Analysis
Values represent mean ± SEM with 2-4 independent experiments conducted with 2-4
biological replicates. Differences between groups were determined with one-way or two-way
ANOVA followed by a Bartlett’s post-hoc test with or Tukey’s multiple comparison test
respectively with p<0.05 (Prism 7 for Mac OS X, Graph Pad Software, Inc. La Jolla, CA 92037).
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CHAPTER 3
RESULTS
Doxorubicin and Resveratrol Effects on Cell Viability
The MTT (MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide))
concentration response assays showed DOX reduced cell viability at concentrations of 3µM
(p<0.0385) and 5 µM (p<0.0071) within 24 h compared to control (Figure 4A). DOX at
concentrations of 0.5, 1 and 2 µM did not have significant effects on cell viability. A dose
response assay performed at 48 h showed toxicity at all concentrations of DOX (p<0.0001)
relative to control (Figure 4B). MTT assays performed at 8 h with 1 h RES pretreatment
indicated that 5 µM RES pretreatment was ineffective in mitigating DOX induced cytotoxicity
while the higher RES concentration of 7.5 µM was slightly more effective (Figure 5A). DOX
concentration of 1 µM coupled with 5 µM RES pretreatment had significantly reduced cell
viability (p<0.0011) when compared to control but 1 µM DOX coupled with 7.5 µM RES
pretreatment did show a significant decline. DOX at 2 µM had significantly reduced cell viability
in both cells treated with 5µM RES (p<0.0003) and 7.5 µM RES (p<0.0004). Cells treated with 4
µM DOX and 5 µM RES showed reduced cell viability (p<0.0246) while cells pretreated with
7.5 µM RES did not show a significant decline in viability. MTT performed at 24 h showed a
significant decline between control vs. 4 µM DOX (p<0.0481) (Figure 5B). Additional declines
were observed between 5 µM RES vs. 5 µM RES+2 µM DOX (p<0.0453) and 5 µM RES+ 4 µM
DOX (p<0.0347). Additional declines were also observed between 7.5 µM RES vs. 7.5 µM
RES+4 µM DOX (p<0.0066) and 7.5 µM RES+1 µM DOX vs. 7.5 µM RES+4 µM DOX
(p<0.0396).
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Figure 4: DOX cytotoxic effects HK-2 cell viability using MTT. DOX dose response at 24 h
(A) and DOX dose response at 48 h (B). Bar graph values represent Mean ± SEM for two
independent experiments.

Figure 5: Protective effects of RES against DOX cytotoxic effects HK-2 cell viability using
MTT. RES was unable to protect against DOX induced cytotoxicity at (A) 8 h. RES was able to
protect against significant loss of cell viability at 24 h (B) with no significant decreases between
groups. Bar graph values represent Mean ± SEM for four independent experiments.
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Oxidative Stress: Protein Carbonylation
Preliminary data indicated that RES decreased protein carbonylation at both
concentrations relative to control (Figure 6). DOX alone appears to increase protein
carbonylation relative to control and RES co-administered with DOX showed a decline in
protein carbonylation relative to control (Figure 6). These results are based on one replicate and
further experiments are required to determine statistical significance.
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Figure 6: DOX treatment increased protein carbonylation in HK-2 cells. Western blot lanes
correspond to the above graph (1-9). Bar graph values represent Mean ± SEM for three
independent experiments run with one biological replicate.
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Western Blot: Cytochrome C Leakage
DOX at 1 and 2µM alone did not cause significant leakage of cytochrome C (cyt C) from
the mitochondria into the cytosol relative to control as confirmed by western blot (Figure 7).
Additionally, RES alone or RES co-administered with DOX did not significantly decrease cyt C
leakage from the mitochondria into the cytosol relative to control within the 24 h treatment
period. Cyt C is located in the inner membrane of the mitochondria and initiate apoptosis. The
lack of an observed difference in cyt C leakage may be attributed to the short experimental time
course and the localization of the protein.
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Figure 7. Cytochrome C leakage from HK-2 cells treated with various concentrations of
DOX and RES. Cytochrome C leakage was not significantly increased or decreased relative to
control or among treatment groups. Bar graph values represent Mean ± SEM for three
independent experiments.
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Western Blot: SIRT1 and PGC1a
SIRT1 expression was decreased significantly in 2 µM DOX (p<0.0142) treated cells
relative to control (Figure 8A). Multiple comparisons revealed significant decreases between 5
µM RES alone and 1 µM and 2 µM DOX alone (p<0.0033 and p<0.0045) respectively (Figure
8A). Significant reductions in SIRT1 were also observed between 7.5 µM RES alone and 1 µM
and 2 µM DOX (p<0.0045 and p<0.0020) respectively (Figure 8). Increases in SIRT 1
expression were observed between 1 µM DOX vs. 7.5 µM RES+1 µM DOX (p<0.0020) and 7.5
µM RES+2 µM DOX (p<0.0403) (Figure 8A). Increases were also observed between 5 µM
RES+1 µM DOX vs. 2 µM DOX (p<0.0304) and 7.5 µM RES+1 µM DOX vs. 2 µM DOX
(p<0.0004) (Figure 8A). These results indicate that SIRT1 is expressed to a higher degree in cells
treated with 5 µM and 7.5 µM RES regardless of the addition of DOX (Figure 8A).
PGC1a expression was higher in RES treated groups relative to control and DOX alone
treated cells although the increases were not significant (Figure 8B). The large variance within
groups indicates that these tests should be repeated but do seem to support increases in SIRT1
mediate increases in PGC1a.
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Figure 8. SIRT1 and PGC1a western blot of HK-2 cells treated with varying
concentrations of DOX and RES. Western blot of SIRT1 (A) and PGC1a (B) and
corresponding treatments: Control (1), RES 5 (2), RES 7.5 (3), DOX 1 (4), RES 5+DOX 1 (5),
RES 7.5+ DOX 1 (6), DOX 2 (7), RES 5+DOX 2 (8), RES 7.5+DOX 2 (9) (p<0.05). Bar graph
values represent Mean ± SEM for two independent experiments.
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Seahorse Analysis: Measurement of Mitochondrial Function
A mitochondrial stress test was performed following a 1 h pretreatment with RES (7.5
µM) and 24 h incubation with DOX (2 and 4 µM). Following treatment, cells were serially
injected with probes to identify parameters of mitochondrial function. The first injection of
oligomycin inhibits the ATP synthase enzyme and results in a decrease in OCR. This decrease
represents mitochondrial respiration linked to ATP production. FCCP uncouples mitochondrial
respiration and increases the cell’s oxygen consumption to its maximum level and enabled us to
calculate the spare or reserve respiratory capacity. The final injection of rotenone/antimycin A
inhibits complex I and III and was used to calculate non-mitochondrial respiration.
Cells exposed to DOX at a concentration of 4 µM showed a significant decrease in basal
respiration (p<0.0083) and 7.5 µM RES+4 µM DOX (p<0.0471) at 24 h but not cells exposed to
2 µM DOX when relative to control (Figure 9A). Basal respiration was significantly decreased
between DOX 2 µM vs. Dox 4 µM (p<0.0047), 7.5 µM RES +2 µM DOX vs. 4 µM DOX
(p<0.0246) and 7.5 µM RES vs. 7.5 µM RES+4 µM DOX (p<0.005) (Figure 9A).
ATP-linked OCR was calculated and results analyzed through a two-way ANOVA and
multiple comparisons (Figure 9C). DOX 4 µM was significantly decreased (p<0.0205) relative to
control (Figure 9C). There were significant declines observed in 2 µM DOX vs. 4 µM DOX
(p<0.0041) (Figure 9C). Multiple comparisons revealed maximal OCR was not significantly
affected among any treatment groups relative control and the only significant decline observed
was between RES 7.5 µM vs. DOX 4 µM (p<0.0022) (Figure 9B). Proton leak was not
significantly affected in any treatment group relative to control (Figure 9E). Surprisingly, proton
leak was decreased between 7.5 µM RES vs. 4 µM DOX (p<0.0402) and vs. 7.5 µM RES +4 µM
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DOX (p<0.0464) (Figure 9E). Proton Leak was also diminished significantly between control
and DOX 4 µM (p<0.0337).
Spare Capacity was not effected in any treatment groups compared to control, but was
decreased in 7.5 µM RES vs. 4 µM DOX (p<0.0022) (Figure 9D).
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Figure 9: Mitochondrial
Stress Test, effects of DOX and RES on ATP production and
mitochondrial respiratory capacity. Basal (A) and Maximal (B) OCR following 24 h exposure
to RES, DOX or RES+DOX. ATP Production (C) spare respiratory capacity (D) and proton leak
(E) following 24 h exposure to RES, DOX or RES+DOX. Bar graph values represent Mean ±
SEM for three independent experiments run with two biological replicates.

Glycolytic stress tests were performed after 24 h treatments with the various
concentrations of RES and DOX. The cells are saturated with glucose and basal ECAR is
assessed. Following basal ECAR assessment, oligomycin is injected to inhibit ATP synthase
thereby driving glycolysis to its maximal capacity. The third and final injection of 2-DG, a
glucose analog, inhibits the first enzyme in the glycolytic pathway known as hexokinase. The
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following observed decrease in ECAR indicates that the ECAR produced in the experiment is
due to glycolysis.
Basal ECAR was assessed but the only significant decline relative to control was in 7.5
µM RES+4 µM DOX group (p<0.0131) (Figure 10A). A significant basal ECAR drop was
observed in 7.5 µM RES vs 2 µM DOX (p<0.0020) and 4 µM DOX (p<0.0032) treated groups
(Figure 10A). There was also significant decrease among 7.5 µM RES treated cells vs. 7.5 µM
RES+4 µM DOX (p<0.0002) and a decrease between 7.5 µM RES+2 µM DOX and 7.5 µM
RES+4 µM DOX (p<0.0157) (Figure 10A).
Glycolytic capacity was reduced in cells treated with 4 µM DOX alone (p<0.0106) and
7.5 µM RES+4 µM DOX (p<0.0098) relative to control cells (Figure 10B). Additionally, cells
treated with 7.5 µM RES alone had significantly higher glycolytic capacity when compared to 2
µM DOX (p<0.0051) or 4 µM DOX (p>0.001) alone (Figure 9B). A significant decline was
observed in cells treated with 7.5 µM RES alone vs. either 7.5 µM RES+ 2 or 4 µM DOX
(p<0.0149, p<0.0001) respectively (Figure 10B).
Glycolytic reserve indicated a significant increase in cells treated with 7.5 µM RES alone
(p<0.0203) relative to control (Figure 10C). Significant decreases in glycolytic reserve were
demonstrated between 7.5 µM RES alone vs. 2 µM DOX (p<0.0019), 4 µM DOX (p<0.0001)
and 7.5 µM RES+4 µM DOX (p<0.0001) respectively (Figure 10C).
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for two independent experiments run with two biological replicates.
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CHAPTER 4
DISCUSSION
Doxorubicin: Cancer Chemotherapeutic
Doxorubicin has been in use as a cancer chemotherapeutic agent since the 1970s despite
the known toxicities associated with administration. The high anti-tumor capability of DOX and
its power to prevent DNA replication is largely why it is still part of the treatment regimen for
breast, ovarian and small cell lung cancer and both acute and chronic lymphoid leukemias. There
is a clear need for better interventions to treat the numerous toxicities associated with DOX,
which could ultimately be responsible for its removal from a patient’s therapy regimen. As stated
previously DOX-associated nephrotoxicity has been studied to a much less extent than other
adverse side effects linked to the anthracycline. DOX progressive and dose-dependent toxicity is
a result of the drug’s accumulation in tissue over time. The preferential accumulation of DOX in
the kidney causes increased capillary permeability and glomerular atrophy (Injac et al., 2008).
The high cytochrome P450 levels in the renal proximal tubule would make the kidney a direct
target for the conversion of DOX to toxic DOX-OL and subsequent formation of ROS (B. S.
Cummings, Zangar, Novak, & Lash, 1999). ROS formation leads to oxidative stress, lipid
peroxidation and subsequent renal damage. Additionally, the high numbers of mitochondria in
the proximal tubule lead to increased damage and mitochondrial dysfunction. The need to
combat renal toxicity is imperative for the continued usage, and use of the natural product RES
in mitigating kidney toxicity would have strong clinical applications.
RES’s anti-oxidant and anti-inflammatory properties have been well documented in the
literature. The additional anti-cancer and anti-tumorigenic properties associated with RES show
its potential in mitigating cancer metastasis in addition to its function as an antioxidant. The
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unique ability of RES to scavenge free radicals could be a potential mechanism against oxidative
stress and lipid peroxidation. At present, it is difficult to determine if RES reduces oxidative
damage by scavenging radicals or if it is capable of inhibiting the generation of free radicals. A
more comprehensive mechanistic study should be performed in order to determine the exact
mechanism by which RES exerts its positive effects. The ability of RES to potentially reduce
oxidative stress and successive damage will be discussed in the following subsections.
Resveratrol Protection Against Doxorubicin Induced Oxidative Stress and Cytotoxicity
Oxidative stress and successive damage are responsible for the irreversible and
progressive toxicity associated with DOX administration. Under normal conditions ROS are
produced at low enough concentrations where the cell is able to detoxify the radicals through
innate antioxidant mechanisms. Excessive production of free radicals, as seen with
administration of DOX, triggers eventual damage that the cell is unable to overcome. However,
it should be noted that even subtle changes due to oxidation of amino acid residues in a protein
polypeptide chain may cause significant alteration in protein higher order structures and cellular
functions (Aryal, Jeong, & Rao, 2014). These alterations indicate that oxidative stress can begin
to cause damage virtually upon onset.
Toxicity mediation through free radical generation, Fe2+-dependent oxidative damage of
biological macromolecules and membrane lipid peroxidation are major players in progressive
toxicity (Tian, Li, Wang, Xie, & Li, 2012). The inability to mitigate protein oxidation and stress
will eventually lead to cell death. Protein carbonylation is a non-specific technique that allowed
us to examine oxidative stress among various treatment groups (Figure 6). Stressed cells produce
an aldehyde or ketone side chain on amino acids, which are then derivitized (see pg. 12) and
analyzed. Proteins are often the first targets of cellular oxidative stress and are commonly used as
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a marker of injury. Cellular dysfunction and disease progression occur as a result of protein
carbonylation (Aryal et al., 2014).
A study by Toldo and colleagues in 2013 demonstrated, in vivo and in vitro, DOX
treatment causes significant damage in cardiomyocytes, over production of ROS and total
protein carbonylation (Toldo et al., 2013). Additionally, Aryal and colleagues demonstrated that
major serum proteins, serum albumin and serotransferrin, were found to be highly carbonylated
under DOX-induced acute cardiotoxicity. DOX effects on cardiomyocytes, as well as cardiac
tissue, has been widely studied, but little is known about DOX-induced protein carbonylation in
HK-2 cells (Aryal et al., 2014). Cardiac tissue is known to have lower levels of antioxidant
enzymes and high levels of mitochondria making it the primary target of toxicity and the reason
it has been heavily studied. Nonetheless, examination of DOX-induced damage in other organs,
i.e. kidney. gave new insight into DOX-induced multi-organ damage. By examining oxidative
damage to the kidney, we were able to better assess and examine a potential way to curb kidney
damage. These findings may lead to new ways to prevent DOX-induced kidney damage and
potentially organ damage as a whole.
DOX has been shown to cause renal damage, but the exact mechanism has remained
elusive. In the past DOX-induced kidney damage has been examined by observing levels of
enzymes capable of detoxifying free radicals. DOX has been shown to induce a glutathione
(GSH) and oxidized-glutathione (GSSG) imbalance as well as lipid peroxidation in kidney tissue
of rats (Injac et al., 2008). The GSH/GSSG ratio is a critical regulator of cellular redox states and
declines in this ratio are closely associated with oxidative stress and disease (Zhou et al., 2014).
Additionally, administration of DOX causes a decrease in GSH, SOD and glutathione-Stransferase (GST) (Liu et al., 2007). GSH and SOD are major players in free radical
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detoxification and decreased levels may indicate the cell’s inability to detoxify ROS at the rate in
which they are being formed. GSTs are enzymes which are strictly specific for epithelial cells of
the proximal and distal tubules in the kidney and are detected in urine when tubular damage has
occurred causing decreased tissue levels (Polak et al., 1999). The imbalance between
GSH/GSSG coupled with decreases in GSH, SOD and GST is indicative of damage and will lead
to toxicity. A potential way to alleviate damage is through the use of RES which has previously
been shown to reduce oxidative stress by increasing expression of SOD and glutathione
peroxidase (GPx1) in human endothelial cells (Spanier et al., 2009). Assessing DOX injury and
potential protection by RES via protein carbonylation analysis was our first step in examining
and conceivably combatting DOX-induced oxidative injury. Oxidative damage was not assessed
at 8 h based on RES’s apparent inability to combat cell damage in the short amount of time
(Figure 5A). Preliminary data showed that DOX alone increased oxidative stress relative to
control and that RES reduced stress when compared to control cells. Cells pretreated with RES
and various concentrations of DOX had decreased protein carbonylation within a 24 h time
period (Figure 5B). It is of interest that like the heart, the proximal tubule of the kidney is high in
mitochondria. RES may have the ability to exert protective effects on cardiac tissue as well as
renal tissue and should be studied further. It is generally accepted that ROS and subsequent
oxidative stress are key players in the initiation of DOX-induced toxicities. This is the first study
to assess protein carbonylation in DOX and RES treated HK-2 cells and demonstrate RES’
capability in reducing oxidative stress caused by DOX which lead us to question if RES could
potentially protect against DOX-induced cytotoxicity by ameliorating decreases in cell viability.
Prolonged oxidative stress and depletion of cellular antioxidant enzymes leads to
irreparable damage and subsequent activation of pro-apoptotic pathways. Apoptosis is one of the
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major mechanisms of cell death in response to cancer therapies (Danial & Korsmeyer, 2004).
The major apoptotic pathway of anticancer drugs is through the loss of mitochondrial membrane
integrity (Kaufmann & Earnshaw, 2000). The loss of mitochondrial membrane integrity causes
the release of cytochrome c from the mitochondria, which in turn activates effector caspases.
Loss of mitochondrial membrane integrity and the subsequent activation of apoptotic pathways
are essential to the drug’s efficacy. However, the need for interventions to prevent DOX from
damaging non-cancerous cells is imperative to its continued use. There have been notably fewer
reports on the effects of DOX-toxicity on non-cancerous cell lines and we endeavored to correct
that with this study.
Previous findings have suggested that DOX induces apoptosis in normal cells vs. tumor
cells by distinctively different mechanisms (Wang et al., 2015). This analysis demonstrated
DOX-induced apoptosis in endothelial cells and cardiomyocytes was a result of a H2O2-mediated
mechanism that was largely independent of p53 activation. However, this was not the case for
tumor cell lines, as p53 tumor suppressor played a crucial role in inducing apoptosis in DOXtreated cells (Wang et al., 2015). The determination that tumor cell lines and normal cell lines
activate apoptosis differently gives us a potential conduit to treat toxicity in non-cancerous cells
without altering the effectiveness of DOX on cancer cells.
DOX has previously been shown to produce dose-dependent and progressive toxicity.
Assessing HK-2 cell’s response to varying concentrations of DOX was the first phase in
quantifying dose-dependent progression of toxicity. HK-2 cell’s mitochondrial activity is
constant and therefore an increase or decrease in the number of viable cells is linearly related to
mitochondrial activity (van Meerloo et al., 2011). The concentration of formazan was measured
to determine changes in cell viability in the MTT assay. HK-2 cells exposed to DOX for 24 h
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showed a significant decrease only at the two highest concentrations (Figure 4A). At 48 h, cell
viability was decreased even at the lowest concentration of 0.5 µM (Figure 4B). These results
confirmed that over time DOX, even at low concentrations, will lead to dose-dependent
progressive toxicity confirming previous studies. We attempted to mitigate the decrease in cell
viability through the use of RES. As discussed previously RES has the ability to upregulate
endogenous antioxidants. The upregulation of SOD, GST, catalase and GPx1 provide a defense
against oxidative stress (Y. Li, Cao, & Zhu, 2006). It is not known whether RES is directly
cytoprotective but the upregulation of cellular antioxidants indirectly protects against cell
damage and death.
We were able to determine RES’s ability to reduce or protect against oxidative stress
relative to cell death. Cells pretreated with 5 µM RES and 1, 2 and 4 µM DOX were not able to
prevent a significant decline in cell viability within the 8 h time course (Figure 5A), indicating
that a concentration of 5 µM RES is not significant enough to protect against DOX induced
cytotoxicity. However, 1 h pretreatment with RES at the higher concentration of 7.5 µM was
able to prevent significant reductions in cell death in DOX treatments of 1 and 4 µM but
interestingly not at 2 µM. The results show that the 8 h exposure is not enough time for lower
concentrations of RES to mitigate cytotoxicity and is observed by the inability of the cell to
reduce oxidative stress and subsequent damage. Even at higher concentrations, a longer exposure
time would be more ideal to determine protective effects of RES on DOX treated cells. Cells
exposed to RES pretreatments (5 and 7.5 µM) for 24 hours and accompanying concentrations of
DOX (1, 2 and 4 µM) showed no significant decline in cell viability (Figure 5B). No significant
decline in cell viability shows RES is capable of protecting HK-2 cells against DOX-induced
cytotoxicity. Cells treated with RES alone had higher cell viability than control cells which

36

confirms previous studies that RES itself is cytoprotective. We can conclude that pretreatment
with the chosen RES concentrations shows potential to decrease cytotoxicity that accompanies
DOX administration within 24 h. RES should be assessed after longer exposure (48 h and 72h) to
determine if it is better able to protect against DOX-induced oxidative stress and cytotoxicity and
to confirm that it does not lose its ability to protect against cell death. There is evidence that
RES’s ability to induce pro-oxidant effects and resist cytotoxicity is time-dependent (Martins et
al., 2014) and should be further examined in longer experimental time courses. These initial
results verify RES’s ability to decrease oxidative damage and subsequent cell death within a 24 h
time period and further experiments should be performed.
Resveratrol Protection Against Doxorubicin Induced Cytochrome C Leakage
The key role that mitochondria play in the regulation of apoptosis have been established
in various studies. The release of different pro-apoptotic proteins that are normally present in the
intermembrane space of these organelles has been observed during the early stages of apoptotic
cell death (Cai, Yang, & Jones, 1998). Among the proteins released from the mitochondrial inner
membrane is cyt C. Cyt C is an essential component of the electron transport chain (ETC) and a
key regulator of apoptosis in the mitochondria. The cyt C protein functions as a single electron
carrier in the final step of the ETC (Huttemann et al., 2011). During programmed cell death cyt C
is released from the mitochondria into the cytosol where it binds to Apaf1 to activate a series of
caspase cascades (Cai et al., 1998). As previously discussed, mitochondrial outer membrane
permeabilization is a key initial step in apoptosis.
Mitochondrial membrane permeabilization occurs through several mechanisms and is
also referred to as the mitochondrial permeability transition (MPT). The first pathway involves
the induction of MPT through the opening of non-specific pores in the inner membrane leading
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to osmotic swelling of the mitochondrial matrix, mitochondrial uncoupling, rupture of the outer
membrane and release of proteins like cyt C (Robertson, Orrenius, & Zhivotovsky, 2000; Yang
& Cortopassi, 1998). A second mechanism capable of inducing mitochondrial membrane
permeabilization is through the Bcl-2 family of proteins. Bcl-2 proteins, specifically Bax, are
capable of inducing the release of cyt C, independent of MPT, through the induction of voltagedependent ion channels (VDAC). VDAC is associated with most of the metabolite flux across
the mitochondrial outer membrane (Colombini, 1983). The third pathway is also MPTindependent and initiates cyt C release in a volume-dependent manner through mitochondrial
swelling which leads to permeabilization of the mitochondrial outermembrane (Gogvadze,
Orrenius, & Zhivotovsky, 2006). Last, there is recent evidence to suggest that caspase-2 is also
capable of mediating the release of cyt C and subsequent activation of downstream caspases
(Gogvadze et al., 2006). It is clear that mitochondrial membrane permeabilization and
subsequent cyt C release is a key step in the initiation of apoptosis. Understanding and
modulation of these pathways experimentally may result in new techniques to mitigate apoptosis
and should be studied more extensively.
Previous in vivo findings have shown DOX treatment causes cyt C release and apoptosis
at much higher levels than untreated animals (Childs, Phaneuf, Dirks, Phillips, & Leeuwenburgh,
2002). Green and colleagues demonstrated that DOX increased cyt C efflux indicating
mitochondrial dysfunction which lead to a change in mitochondrial membrane permeability that
was not observed in the mitochondria of control animals (P. S. Green & Leeuwenburgh, 2002).
Additionally, both studies showed a marked increase in caspase-3 activity indicating apoptosis
and the likelihood that caspase-3 is the primary effector caspase involved. In vitro studies of
cardiac myocytes treated for 24 h with DOX showed increased leakage of cyt C into the
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cytosolic compartment relative to untreated cells (Kotamraju, Konorev, Joseph, &
Kalyanaraman, 2000). Once again various studies have been performed using animal cardiac
tissue and cardiac cell lines but little information is available on DOX-induced cyt C leakage
regarding other organs and cell lines.
The therapeutic effects of RES as a potential anti-cancer agent as well as a
cardioprotective agent have been studied extensively. In a study completed this year, RES was
given prophylactically and therapeutically with DOX and results compared in rats (Shoukry et
al., 2017). Prophylactic administration was defined as pre-treatment with RES before DOX and
therapeutic defined as RES treatment post DOX administration. The study demonstrated that
DOX induced cardiac fibrosis but when RES was administered therapeutically cardiac fibrosis
was decreased. Additionally, prophylactic supplementation of RES was more effective in
reducing fibrosis than when RES was administered therapeutically (Shoukry et al., 2017).
Apoptosis was examined by looking at Bax, Bcl-xl and caspase 3 expression. DOX led to an
increase in myocardial apoptosis and a significant increase in caspase 3. Therapeutic treatment
with RES reduced myocardial apoptosis but not as significantly as when RES was administered
prophylactically (Shoukry et al., 2017). RES, like DOX, has been studied widely in respect to its
cardioprotective abilities but less so in other cells and tissues.
For the first time HK-2 cells treated with DOX, RES and DOX+RES were examined to
determine if DOX increases cyt C leakage from the mitochondrial inner membrane. The results
indicated that HK-2 cells treated with DOX alone had no increase or decrease in cytosolic levels
of cyt C and cells treated with RES alone or co-administered with DOX showed no significant
increase or decrease relative to control (Figure 7). Cyt C is normally bound to the inner
mitochondrial membrane by an association with anionic phospholipid cardiolipin, where it can
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reversibly interact with complexes III and IV of the respiratory chain and dissociation from of
cyt C from cardiolipin may be the critical first step in caspase activation (Petrosillo, Ruggiero,
Pistolese, & Paradies, 2001). Previous studies done by our lab showed no discernible changes in
cardiolipin levels within 24 h supporting our results that cyt C has not yet dissociated and
translocated within this time period.
Within the 24 h time course it is possible that this terminal step of the ETC is not affected
or that DOX at concentrations of 1 and 2 µM are slower to effect apoptosis initiation and
translocation of the protein from the inner mitochondrial membrane to the cytosol. Additionally,
the kidneys have higher levels of detoxifying enzymes than the heart. It is possible that within 24
h cells are able to detoxify radicals and protect against the initiation of apoptosis. Eventually
these enzyme levels will be depleted and apoptosis initiated and a longer period of study is
indicated to ascertain RES potential protection against apoptosis. These findings are confirmed
by our cell viability assay that DOX administered at concentrations of 1 and 2µM are not yet
toxic to the cell within 24 h time period (Figure 5).
Resveratrol: A Mechanistic Approach
Sirtuin 1 (Sirt1) functions as a protein deacetylase to remove acetyl groups on proteins in
a NAD-dependent manner. Sirt1 is known to modulate a number of transcription regulators,
including PGC1a, a nuclear hormone receptor coactivator that promotes mitochondrial
biogenesis (Koo & Montminy, 2006). PGC1a is required for mitochondrial biogenesis but
previous assays of PGC1a activation of upstream effectors have not consistently predicted the
subsequent biogenic process (Beeson et al., 2010). Previous studies have demonstrated that
SIRT1 modulates the activity of a number of transcriptional regulators in mammals, most
notably, PGC1a (Koo & Montminy, 2006). Studies have also shown that resveratrol improves
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energy balance and increases mitochondrial function in mice by stimulating SIRT1-mediated
deacetylation of PGC1a (Baur et al., 2006; Lagouge et al., 2006).
We endeavored to examine the capability of RES to potentially induce PGC1a through
SIRT1 increases and in turn promote mitochondrial biogenesis. Our results demonstrated that
RES treated groups had a higher expression of SIRT1 than cells treated with either concentration
of DOX (Figure 8A). RES-mediated SIRT1 increases are supported by previous studies (Baur et
al., 2006; Koo & Montminy, 2006; Lagouge et al., 2006) and indicate that RES is capable of
improving mitochondrial function through SIRT1 activation. However, based on our results we
are unable to definitively determine that it is through SIRT1-mediated modulation of PGC1a.
The increases in PGC1a (Figure 8B) observed indicate that this is a distinct possibility but
further experiments are required to positively determine the extent to which PGC1a is involved.
It is clear that SIRT1 induction is a probable mechanism for RES to protect against DOXinduced toxicity.
Resveratrol Protection Against Doxorubicin Induced Mitochondrial Damage
Mitochondria play a major role in Ca2+ homeostasis, ROS generation, redox balance,
cellular proliferation and apoptosis (Whitaker et al., 2015). The kidneys are second only to the
heart in mitochondrial abundance and oxygen consumption at rest (Pagliarini et al., 2008). The
proximal tubules of the kidney use the majority of oxygen consumption for ATP generation and
contain most of the mitochondria that power the active reabsorption of glucose, ions and other
metabolites as well as synthesize protein (Forbes, 2016). Damage to the mitochondria of
proximal tubule cells, i.e. HK-2 cells, have the potential to cause significant damage to the
kidney. In the past mitochondrial damage has been difficult to quantify but in this novel study we
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were able to compute mitochondrial changes during both oxidative phosphorylation and
glycolysis.
Mitochondrial dysfunction is an early indicator of DOX-induced apoptosis and
subsequent oxidant production (P. S. Green & Leeuwenburgh, 2002). The ability to restore
mitochondrial function and/or to prevent initial damage would have strong clinical implications.
RES has been shown to produce mitochondrial biogenesis. However, the ability to do so may be
limited by the remaining mitochondrial function and ATP levels but through stimulation of
mitochondrial biogenesis RES may promote organ recovery and return of cellular functions
(Beeson et al., 2010). Ideally a pre-treatment with RES would protect against initial injury while
simultaneously stimulating mitochondrial biogenesis.
The Seahorse XFp Analyzer is a unique tool allowing the simultaneous monitoring of the
two energy pathways of the cell. The majority of cells possess the capability to shift between the
two pathways allowing cells to adapt to environmental changes. Previously there were only highthroughput assays assessing changes in mitochondrial gene expression but these assays lacked
the capability to evaluate mitochondrial biogenesis. The mitochondrial and glycolytic stress tests
are the first high-throughput assays to examine the changes in mitochondrial respiration and an
improved approach for examining mitochondrial toxicity (Beeson et al., 2010). This study is the
first to look at the direct effects of DOX on mitochondria as well as the ability of RES to
potentially mitigate mitochondrial toxicity and promote mitochondrial biogenesis.
Primary cultured HK-2 cells are a valuable model for evaluating mitochondrial toxicity
because they acquire their energy from oxidative phosphorylation and maintain differentiated
functions and membrane polarization (Nowak & Schnellmann, 1996). The kidneys primarily
undergo aerobic metabolism and mitochondrial damage leads to decreased aerobic metabolism
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and ATP, disruption of cellular functions, cell injury and death (Beeson et al., 2010). HK-2 cells
exhibit in vivo levels of aerobic metabolism, are not glycolytic and retain higher levels of
differentiated functions making them an appropriate experimental model for study (Beeson et al.,
2010). Using seahorse technology and primary culture HK-2 cells we were able to examine the
cellular targets of toxicity specific to a primary renal cell line and the potential protective effects
of RES against DOX induced kidney damage.
The cell mitochondrial stress test was performed and for the first time we were able to
quantify basal OCR, ATP-linked OCR with proton leak, maximal respiration, spare capacity and
non-mitochondrial OCR in control and treated HK-2 cells. The basal measurements established a
baseline prior to serial injection with various inhibitors and electron transport chain uncouplers.
The baseline readings establish the threshold below which the cells would be unable to sustain
oxidative phosphorylation to meet energy demand. Living cells do not store ATP, they produce it
continually and on demand. Therefore, cells constantly consume oxygen and fuel substrates and
the demand for ATP in cells controls the rate of OCAR (Pike Winer & Wu, 2014).
Cells treated with 7.5 µM RES tended to increase basal respiration relative to control
(Figure 9A). Although it was not a statistically significant increase it does show RES may
potentially increase the threshold and therefore the cell’s ability to meet an increased energy
demand. On the other hand, baseline readings showed that cells treated with 4 µM DOX alone
had a significantly lower threshold than control cells and there was a significant decline in basal
respiration between cells treated with 2 µM vs. 4 µM DOX (Figure 9A). Additionally, 7.5 µM
RES+4 µM DOX treated cells had reduced basal respiration relative to 7.5 µM RES alone as well
as control cells. It would appear that RES is capable of protecting against a significant decline at
2 µM DOX but the threshold is too low for it to exert protective effects at 4 µM and a higher
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concentration of RES may be indicated to adequately protect against a decline in basal
respiration.
Metabolism strips electrons from fatty acids, sugars and amino acids, and they
accumulate on the soluble electron carrier NADH and on protein-bound FADH2 (K. Green,
Brand, & Murphy, 2004). The electrons are then passed down the mitochondrial respiratory
chain to drive ATP synthesis through oxidative phosphorylation (K. Green et al., 2004). The first
injection of oligomycin halts the electron passage down the chain by acting as a sort of roadblock
against transport. The corresponding change in respiration quantifies the amount of basal
respiration actually being used for ATP production and is expressed as ATP-linked OCR.
Previous studies reveal that “healthy” individuals have a high ATP linked OCR or an increased
ATP demand. A decrease would indicate low ATP demand, a lack of substrate and/or severe
damage to oxidative phosphorylation, impeding the flow of electrons resulting in a lower ATPcoupled OCR (Chacko et al., 2014). Chacko’s study supported our results that RES treatment
increases ATP-linked OCR and ATP demand. RES when coupled with DOX treatment reduced
declines in ATP-coupled OCR that were observed in cells only exposed to DOX (Figure 9C).
The protective effects of RES against this drop indicate protection against damage to oxidative
phosphorylation.
The remaining basal respiration represents the “proton leak” which has two possible
implications for the mitochondria and both will be discussed. Functional mitochondria move
electrons down the gradient from NADH/FADH2 to O2 while conserving redox energy by
simultaneously pumping protons across the intermembrane to build up the proton
electrochemical potential that is used by ATP synthase to make ATP (K. Green et al., 2004). The
above is an example of the mitochondria using protons as a regulatory mechanism for ATP
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production. However, in some instances of mitochondrial damage, protons leak back into the
matrix without ever forming ATP thereby reducing energy production. Higher levels of proton
leak indicate fewer protons available to drive ATP synthase to make ATP and may correspond to
a decrease in energy production. ATP production tended to increase in RES treated cells alone
relative to control, although not significantly (Figure 9C). Cells treated at the higher
concentration of DOX did show a significant decline in ATP production relative to control but
when pre-treated with RES this decline was alleviated. Further declines were only observed in
comparison to RES treated cells alone and confirmed that pre-treatment with RES protects
against a decline in ATP production.
The most interesting results were observed when quantifying proton leak. There was no
change in proton leak in any treatment groups relative to control but RES treated cells alone had
increased proton leak when compared to the higher concentration (4 µM) of DOX treated cells
alone and those pre-treated with RES (Figure 9E). Previous studies have shown that increased
calcium transport can manifest changes in proton leak (Chacko et al., 2014). It is possible that
administration of RES may increase calcium transport and account for the increase in proton leak
shown rather than as an indicator of damage. The lack of decline in ATP production in RES
treated groups would support that there is another mechanism at work and should be examined in
future studies. Additionally, diminished proton leak may be a potential compensatory mechanism
in mitigating the decline in ATP production in response to DOX-induced stress. Maximal
activity was examined further by uncoupling ATP production from the electron transport chain
to examine OCR capacity.
The electron roadblock was offset by injection of FCCP allowing us to examine the
effects of uninhibited electron flow through loss of the proton gradient. The uncoupling of the
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electron transport chain from ATP production enabled us to quantify its maximal activity. As
previously mentioned, metabolism strips electrons from fatty acids, sugars and amino acids. The
stimulation by FCCP and resultant drive to maximal capacity causes the rapid oxidation of those
metabolic substrates to meet the increased energy demands. Interestingly, there was no effect on
maximal OCR capacity in any treatment group when compared to control indicating that DOX
and RES, whether co-administered or alone, do not appear to significantly affect the maximal
activity of the electron transport chain relative to control (Figure 9B). No change in maximal
activity would imply that maximal OCR was not yet effected by administration of DOX and/or
RES, and that cells were able to meet the metabolic challenge within the exposure period.
Spare capacity was calculated to determine how closely the cell is respiring to its
theoretical maximum. Spare capacity was calculated by subtracting maximal respiration from
basal respiration and the difference quantified the cell’s ability to respond to an increase in
energy demand. When damage to the mitochondria occurs, spare capacity is called upon to meet
increased energy demand and prevent damage. Studies have shown that depletion of this reserve
leads to excessive damage and cell death (Hill, Dranka, Zou, Chatham, & Darley-Usmar, 2009).
Oxidative stress and formation of ROS can increase OCR and deplete reserve capacity and
inhibit respiration (Hill et al., 2009).
Intriguingly, spare capacity was not significantly increased or decreased in any of the
treatment groups relative to control (Figure 9D). RES alone did not increase significantly when
compared to control but it should be noted that there was a tendency to increase. The only
significant decrease observed was between RES alone and the higher concentration of DOX and
we would expect to see diminished spare capacity in these cells. These results indicate RES’s
potential to mitigate a decline in spare capacity by improving the cells ability to respond to an
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increased energy demand. RES appears to be protecting against a reduction in spare capacity
allowing the cells to function closely to their theoretical maximum. Non-mitochondrial
respiration was assessed by an injection of rotenone/antimycin A that shut down electron
transport complexes I and III respectively. Rotenone coupled with antimycin A effectively
turned off mitochondrial respiration and allowed us to delineate between mitochondrial
respiration and non-mitochondrial respiration.
The second energy pathway of the cell was assessed using the Glycolytic stress test assay
and was performed to measure metabolic activity through ECAR. Glycolysis is the conversion of
glucose to pyruvate and then pyruvate to lactate in the cytoplasm or CO2 and H2O in the
mitochondria. Cells utilize glucose to produce pyruvate which in turn produces ATP, H2O,
NADH and protons. The relationship between ECAR and glycolytic rate can be confounded by
other acidification mechanisms, i.e. CO2 (Mookerjee, Goncalves, Gerencser, Nicholls, & Brand,
2015). It should be noted that in this study the baseline OCR/ECAR ratio was <4 signifying that
CO2 made a negligible contribution to ECAR and the observed results were from glycolysis
alone. A major component or ECAR is the glycolytic production of lactate (M. Wu et al., 2007).
Lactate increases acidification and lowers pH; therefore the media is devoid of glucose for the
first measurements to determine accurate acidification unrelated to glycolysis (Mookerjee et al.,
2015). The saturating injection of glucose leads to the conversion of glucose to pyruvate and
pyruvate to lactate triggering proton extrusion into the medium and acidification of the medium
surrounding the cell. The extrusion of protons from glucose catabolism permitted ECAR to be
measured a second time and basal level glycolysis calculated.
Basal glycolysis was increased in RES alone treated cells, and cells treated with DOX
alone had a severe decline in basal ECAR relative to RES treated cells at both concentrations
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(Figure 10A). However, when the lower concentration of DOX was pre-treated with RES this
decline was ameliorated but it was not able to prevent a significant decline when coupled to the
higher concentration of DOX. The inability to prevent a decline in basal glycolysis was observed
in OCR as well. A higher concentration of RES may be indicated when administered with the
higher concentration of DOX. RES appears to be protective against a decrease in ECAR when
co-administered with 2 µM DOX cells showing that RES is capable of protecting against
diminished basal glycolysis at this concentration (Figure 10A).
Oligomycin was injected to “max out” glycolysis by shutting down oxidative
phosphorylation and forcing cells to use the glycolytic pathway to capacity. When cells
experience loss of mitochondrial ATP production due to inhibition of oxidative phosphorylation
or by oligomycin, they augment their glycolytic flux to make more ATP from glycolytic
pathways in order to maintain cellular ATP homeostasis (M. Wu et al., 2007). The increased
glycolytic flux in response to deficiency in mitochondrial ATP production is known as the
glycolytic capacity (Pike Winer & Wu, 2014). The glycolytic capacity of cells subjected to 4 µM
DOX was significantly decreased compared to control as were cells treated with RES plus the
higher concentration of DOX (Figure 10B). Treatment with RES alone increased capacity and,
although RES+ 2 µM DOX was decreased compared to RES alone, it was not decreased when
compared to control demonstrating conceivable protection against a loss of ATP production.
Again, we observed the inability of RES to protect against loss of ATP production.
The glycolytic reserve was calculated to indicate how well the cell was able to respond to
its theoretical maximum. Cells treated with RES alone functioned well above their theoretical
max compared to control (Figure 10C). Although RES+2 µM DOX and RES+4 µM DOX
treatment groups were decreased in comparison to RES alone, neither was decreased relative to
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control. Furthermore, the RES+2 µM DOX treatment group was increased relative to control.
RES appears to be better able to mitigate damage at the lower DOX concentration but still
exhibits a partial protection between 4 µM DOX and RES+4 µM DOX.
In order to confirm the experimental ECAR was produced by glycolysis, 2-deoxy-glucose
(2-DG) was injected. 2-DG is a glucose analog that inhibits glycolysis via inhibition of glucose
by competitively binding to glucose hexokinase, the first enzyme in the glycolytic pathway
inhibitor. We observed a dramatic drop in ECAR that confirmed the experimental ECAR was
produced by glycolysis.
When comparing OCR and ECAR, it appears that RES exerts a more protective effect on
the glycolytic pathway than on oxidative phosphorylation. During oxidative phosphorylation, it
appears that basal respiration and ATP production are so severely decreased between DOX 2 and
4 µM that RES is not able to overcome and protect against toxicity. These decreases may be a
direct result of the cell using proton leak pathways to regulate ATP production allowing those
treatment groups to still function relatively close to their theoretical max. Basal ECAR was
decreased in control vs. 2 and 4 µM DOX as well as between RES+2 µM DOX and RES+4 µM
DOX. Just as in OCR, it appears that the damage occurs between 2 and 4 µM DOX and RES is
not able to protect against damage. RES was better able to protect against significant decreases in
glycolytic capacity and reserve overcoming the initial decrease of basal ECAR. The results
suggest that RES has less of a protective effect on mitochondrial rate (OCR) than glycolytic rate
(ECAR).
The utilization of Seahorse technology has potential widespread clinical implications.
The ability of RES to stimulate mitochondrial biogenesis even in the presence of cytotoxic DOX
is a potential therapeutic option to mitigate DOX induced nephrotoxicity through recovery and
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promotion of cellular function. The Seahorse XFp Analyzer provides us with the first tool to
quantify bioenergetics in different cellular models. This high-throughput assay quantified
mitochondrial function and permitted a way to predict a response to a given treatment. We
obtained a comprehensive bioenergetics profile for HK-2 cells and their response to treatments
with RES, DOX and RES + DOX respectively. By showing RES’s positive effect on
mitochondrial energetics we have introduced a clinically relevant way to mitigate potential
DOX-induced mitochondrial toxicity in the epithelium of mitochondria-rich renal proximal
tubular cells.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
This thesis has shown the ability of RES to protect DOX-induced nephrotoxicity and may
potentially have many clinical implications. RES has shown promise in its ability to improve
mitochondrial function and mitigate DOX toxicity by decreasing oxidative stress, improving cell
viability and protecting against mitochondrial damage in both oxidative phosphorylation and
glycolytic pathways. This thesis has also proposed a potential mechanism that RES’s ability to
induce SIRT1 is responsible for its protective abilities against DOX-induced damage.
RES shows potential in reducing oxidative stress and cell death but the exact mechanisms
are still unknown. Given that proteins are often the immediate targets of cellular oxidative stress,
it is of utmost importance to determine how adductions of reactive nucleophiles irreversibly alter
protein structure and function. I would propose to examine 4-hydroxynonenal (4-HNE) to
examine the extent of lipid peroxidation in DOX treated cells and the capability of RES to
protect against it. Additionally, I would like to determine if DOX induces the cleavage of
caspases 3 and 9 to determine the exact initiation of the pro-apoptotic pathway.
Western blotting indicated that there was no change in cyt-C leakage among any groups
relative to control. I would propose examination of cyt C leakage after 48 and 72 h to determine
if the 24 h time course was not enough time for the protein to translocate from the inner
mitochondrial membrane to the cytosol. The examination of ATP synthase in mitochondrial and
cytosolic fractions would further determine the extent to which mitochondrial membrane
integrity is compromised and should be assessed within the same time courses as cyt C.
Our initial study demonstrated that SIRT1 levels are higher in RES treated cells but we
were unable to determine definitively if SIRT1 modulates increases in PGC1a. Additionally, the
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variability within groups is a concern and should be addressed through further experimentation.
However, the increases in PGC1a indicate that this is still a viable potential mechanism and
longer experimental time courses may reveal statistically significant increases that would
confirm our proposed mechanism.
Examination of both energetic pathways gave us unique insight into DOX effects on
oxidative phosphorylation as well as the glycolytic pathway. The observed protection of RES at
the lower concentration of DOX supported our hypothesis, but indicated higher concentrations of
RES may be necessary when DOX is administered at higher concentrations. Additionally,
performing the mitochondrial stress test and the glycolytic stress test at 48 h and 72 h time
courses would give us more definitive data on RES ability to protect against DOX-induced
toxicity.
Limitations
RES and its metabolites pose both physiological and pharmacokinetic problems. The
low bioavailability of RES as well as the various routes of administration has made it difficult
to uniformly quantify proper dose and subsequent response. Furthermore, RES is not regulated
by the FDA because it is a natural compound. Controlled regulation and formulation of the
compound is imperative for clinical application.
Time, as in most cases, has been my greatest limiting factor. The data have supported
our hypothesis that RES is capable of preventing DOX-induced damage, but further
experiments are required to further elucidate the mechanisms of protection.
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APPENDIX B: LIST OF ABBREVIATIONS
DOX...doxorubicin
DNA…deoxyribonucleic acid
Top2…topoisomerase II
ROS…reactive oxygen species
DOX-OL…doxorubicinol
NADPH…nicotinamide adenine dinucleotide phosphate
P450R…cytochrome P450 reductase
Fe…iron
H2O2…hydrogen peroxide
OH…hydroxyl radical
AST…aspartate aminotransferase
ALT…alanine aminotransferase
MDA…malondialdehyde
Vmax…maximum velocity
NOS…nitric oxide synthase
NO…nitric oxide
iNOS…inducible nitric oxide synthase
eNOS…endothelial nitric oxide synthase
RES…resveratrol
HPLC…high performance liquid chromatography
CVD…cardiovascular diseases
ALF…acute liver failure
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ATP…adenosine triphosphate
HK-2…human noncancerous renal proximal tubular epithelial cells
ATCC…American type culture collection
DMSO…dimethylsulfoxide
MTT…3-4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium Bromide
HBSS…hank’s buffered saline solution
OD…optical density
SIRT1…sirtuin 1
TBST…tris-buffered saline-tween
HEK293…human embryonic kidney whole cell lysate
PGC1a…peroxisome
BSA…bovine serum albumin
PBST…phosphate-buffered saline-tween
OCR…oxygen consumption rate
ECAR…extracellular acidification rate
FCCP…carbonyl cyanide-4-trifluoromethoxy phenylhydrazone
SEM…standard error of the mean
ANOVA…analysis of variance
Cyt C…cytochrome C
ETC…electron transport chain
MPT…mitochondrial permeability transition
VDAC…voltage-dependent ion channels
2-DG…2-deoxy-glucose
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GSH…glutathione
GSSG…oxidized glutathione
SOD…superoxide dismutase
GST…glutathione-s-transferase
P53…tumor suppressor protein
GPx1…glutathione peroxidase 1
4-HNE…4-hydroxynonenal
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Education
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“Uric Acid-Induced Adipocyte Dysfunction is Attenuated by HO-1
Upregulation: Potential Role of Antioxidant Therapy to Target Obesity”
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“The Association of Metabolic/Inflammatory Biomarkers and Insulin
Resistance in Obese Children from West Virginia”
• Collaborators: Yoram Elitsur, MD; Deborah Preston, BS; Komal
Sodhi, MD
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• Research conducted at Marshall University School of Medicine
“Su1885 Insulin Resistance is a Key Factor for Metabolic and
Inflammatory Biomarkers in Children with Obesity”
• Collaborators: Yoram Elitsur, MD; Deborah Preston, BS;
Komal Sodhi, MD
• Research conducted at Marshall University School of Medicine
“20-HETE and Circulating Endothelial Cells, a Unique Vascular
Profile Related to CVD in Morbidly Obese Appalachian Women”
• Collaborators: Kathleen O’Hanlon, MD; Komal Sodhi, MD;
Eamonn Maher, MD; Zeid Khitan, MD; Nitin Puri, MD, PhD;
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“The Existence of a Strong Correlation between Leptin, TNFa and
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Recent Presentations
Oral
December 2017
March 2017
September 2014

“Doxorubicin Cytotoxicity in a Human Proximal Tubular Cell Line
was Attenuated by the Natural Product Resveratrol” Presented to
faculty at Marshall University, Huntington, WV
“Doxorubicin and Nephrotoxicity: Clinical Implications” Lecture
Presented to Marshall University graduate students and faculty as part
of the Spring 2017 Seminar Series, Huntington, WV
“Targeting Endothelial Cells with HO-1 Attenuated Vascular and
67

April 2014

Poster
December 2017
March 2017
March 2015
September 2015

Adipocyte Dysfunction in Mice Fed High Fat Diet” Presented at The
American Heart Association Hypertension Conference, New Orleans,
LA
“20-HETE and Circulating Endothelial Cells: Clinical Implications in
Cardiovascular Disease” Presented as Grand Rounds Lecture for
Cardiology Attending’s and fellows at Joan C. Edwards School of
Medicine, Huntington, WV
“Doxorubicin Cytotoxicity in a Human Proximal Tubular Cell Line
was Attenuated by the Natural Product Resveratrol” Presented at a
OVSOT Conference, West Lafayette, IN
“Doxorubicin Cytotoxicity in a Human Proximal Tubular Cell Line
was Attenuated by the Natural Product Resveratrol” Presented at
Marshall University Research Day, Huntington, WV
“20-HETE and Circulating Endothelial Cells, a Unique Vascular Profile
related to CVD in morbidly obese Appalachian Women. Marshall
University Research Day, Huntington, WV
“The Existence of a Strong Correlation between Leptin, TNFa and BMI
in Morbidly Obese Appalachian Females. American Heart Association
Hypertension Conference, San Francisco, CA
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Marshall University Graduate Student Organization, Member
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American Heart Association, Member
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Marshall University Research Corporation
• Research Assistant
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DARCO International
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National Marketing Campaigns
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•
•
•
•
•
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counterparts
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and sales to corporate office
Completed professional objectives by preparing daily, weekly, and
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management style
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Licensed Series 7 as a Securities Trader per SEC –July 2007
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